+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Combination chemotherapy for high-risk gestational trophoblastic tumour



Combination chemotherapy for high-risk gestational trophoblastic tumour



Cochrane Database of Systematic Reviews 2009(2): Cd005196



Gestational trophoblastic disease (GTD) includes gestational trophoblastic tumour and hydatidiform mole. Many women of reproductive age are affected by this disease although its incidence differs by geographical location. A number of chemotherapy regimens are used for treating the disease, such as methotrexate, actinomycin D and cyclophosphamide (MAC), methotrexate, actinomycin D, cyclophosphamide, doxorubicin, melphalan, hydroxyurea and vincristine (CHAMOC), etoposide, methotrexate and actinomycin (EMA) plus cyclophosphamide and vincristine (CO) (EMA-CO), etoposide, methotrexate and actinomycin (EMA) plus etoposide and cisplatin(EP) (EMA-EP). The efficacy of these drugs has not been systematically reviewed. To determine the efficacy and safety of combination chemotherapy in treating high-risk GTT. Electronic searches of Cochrane Central Register of Controlled Trials (CENTRAL) (Issue 2, 2008), MEDLINE, EMB and CBM, May 2008. Four journals were handsearched and other searching methods were used for identifying more studies. The review included randomised controlled trials (RCTs) or quasi-RCTs of combination chemotherapy for treating high-risk GTT. Patients with placental-site trophoblastic tumour (PSTT), who had received chemotherapy in the previous two weeks, or patients with chemotherapy intolerance were excluded. Two investigators independently collected data using a data extraction form. Meta-analysis was not performed and the review was conducted as a narrative review. One study with 42 participants was included in this review. It indicated that a MAC regimen was better than a CHAMOCA regimen for high-risk GTT because of lower toxicity. The quality of the study was unclear. The methodological limitations of the included study prevent any firm conclusions about the best combination chemotherapy regimen for high-risk GTT. High quality studies are required.

(PDF emailed within 0-6 h: $19.90)

Accession: 052173598

Download citation: RISBibTeXText

PMID: 19370618

DOI: 10.1002/14651858.CD005196.pub3


Related references

Combination chemotherapy for primary treatment of high-risk gestational trophoblastic tumour. Cochrane Database of Systematic Reviews 2013(1): Cd005196, 2013

Comparing cisplatin-based combination chemotherapy with EMA/CO chemotherapy for the treatment of high risk gestational trophoblastic neoplasia. European Journal of Cancer 49(4): 860-867, 2013

Combination chemotherapy with methotrexate, etoposide, and actinomycin D for high-risk gestational trophoblastic tumors. Gynecologic Oncology 78(1): 28-31, 2000

Combination chemotherapy with etoposide and cisplatin for high-risk, chemorefractory and recurrent gestational trophoblastic neoplasia. Zhonghua Fu Chan Ke Za Zhi 42(9): 595-599, 2007

Salvage combination chemotherapy with 5-fluorouracil and actinomycin D for patients with refractory, high-risk gestational trophoblastic tumors. Cancer 95(5): 1051-1054, 2002

Combination chemotherapy with 5-fluorouracil, methotrexate and etoposide for patients with high-risk gestational trophoblastic tumors: a report based on our 11-year clinical experiences. Gynecologic Oncology 103(3): 1105-1108, 2006

Tumour vascularity assessed using Doppler ultrasound predicts the risk of resistance to methotrexate chemotherapy in gestational trophoblastic tumours. British Journal of Cancer 85(Supplement 1): 26, July, 2001

High risk nonmetastatic persistent gestational trophoblastic tumour following an abortion. Kathmandu University Medical Journal 5(3): 412-413, 2008

Salvage chemotherapy for high-risk gestational trophoblastic tumor. Journal of Reproductive Medicine 49(6): 438-442, 2004

Secondary chemotherapy for high-risk gestational trophoblastic neoplasia. Gynecologic Oncology 97(2): 618-623, 2005

Etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EMA) chemotherapy for patients with high-risk gestational trophoblastic tumors refractory to EMA/cyclophosphamide and vincristine chemotherapy and patients presenting with metastatic placental site trophoblastic tumors. Journal of Clinical Oncology 18(4): 854-859, 2000

Low-risk gestational trophoblastic neoplasia and methotrexate resistance: predictors of response to treatment with actinomycin D and need for combination chemotherapy. Journal of Reproductive Medicine 55(7-8): 279-284, 2010

Developments in chemotherapy for medium risk and high risk patients with gestational trophoblastic tumors 1979 1984. British Journal of Obstetrics & Gynaecology 93(1): 63-69, 1986

Primary treatment of metastatic high-risk gestational trophoblastic neoplasia with EMA-CO chemotherapy. Journal of Reproductive Medicine 51(10): 767-772, 2006

Reproductive outcomes after multiagent chemotherapy for high-risk gestational trophoblastic neoplasia. Journal of Reproductive Medicine 59(5-6): 204-208, 2014